Related Experiment Videos
A retrospective study of Pseudomonas aeruginosa isolation from clinical sources
E D Anastassiou1, I Spiliopoulou, A Arvaniti
1Department of Microbiology, School of Medicine, University of Patras, Greece.
Abstract:
The incidence of Pseudomonas aeruginosa recovery from blood, urine and other clinical specimens as well as its resistance to various antimicrobials during a 5-year period (1982 to 1986) are reported. The susceptibility patterns to newer antipseudomonad agents of 100 randomly selected P. aeruginosa clinical strains isolated in 1987 is also presented. Our results show an overall P. aeruginosa isolation incidence of 10.6%, with its resistance to routinely used antibiotics being high but relatively low to the newer agents which have not been used extensively in our hospital.
Insights
Pseudomonas aeruginosa is frequently isolated from clinical samples. While resistance to common antibiotics is high, newer agents show promising low resistance rates in this study.
Area of Science:
- Clinical microbiology
- Infectious diseases
- Antimicrobial resistance
Background:
- Pseudomonas aeruginosa is a significant opportunistic pathogen.
- Antimicrobial resistance in P. aeruginosa poses a major clinical challenge.
- Monitoring resistance patterns is crucial for effective treatment.
Purpose of the Study:
- To report the incidence of P. aeruginosa isolation.
- To analyze antimicrobial susceptibility patterns over time.
- To evaluate resistance to newer antipseudomonad agents.
Main Methods:
- Retrospective analysis of clinical specimens (blood, urine, etc.) from 1982-1986.
- Antimicrobial susceptibility testing of 100 P. aeruginosa strains isolated in 1987.
- Evaluation against routinely used and newer antipseudomonad agents.
Main Results:
- Overall P. aeruginosa isolation incidence was 10.6%.
- High resistance rates were observed for commonly used antibiotics.
- Lower resistance rates were noted for newer agents not extensively used.
Conclusions:
- P. aeruginosa is a common isolate in clinical settings.
- Emerging resistance to standard antibiotics necessitates alternative treatments.
- Newer antipseudomonad agents demonstrate potential efficacy due to lower resistance.